Adimmune Corporation (4142) Stock Statistics & Valuation Metrics
Total Valuation
Adimmune Corporation has a market cap or net worth of TWD 7.02B. The enterprise value is TWD 8.70B.
- Market Cap
- TWD 7.02B
- Enterprise Value
- TWD 8.70B
Share Statistics
Adimmune Corporation has 429,507,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 429,507,750
- Owned by Insiders
- ―
- Owned by Institutions
- 2.89%
Financial Efficiency
Adimmune Corporation’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -4.56%.
- Return on Equity (ROE)
- -0.05
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- -4.56%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 2.48M
- Profits Per Employee
- -425.34K
- Employee Count
- 564
- Asset Turnover
- 0.17
- Inventory Turnover
- 1.95
Valuation Ratios
The current PE Ratio of Adimmune Corporation is -48.09. Adimmune Corporation’s PEG ratio is 0.32.
- PE Ratio
- -48.09
- PS Ratio
- 5.03
- PB Ratio
- 1.49
- Price to FCF
- -26.06
- Price to Operating Cash Flow
- -107.36
- PEG Ratio
- 0.32
Income Statement
In the last 12 months, Adimmune Corporation had revenue of 1.40B and earned -239.89M in profits. Earnings per share was -0.57.
- Revenue
- 1.40B
- Gross Profit
- 288.49M
- Operating Income
- -359.55M
- Pretax Income
- -329.77M
- Net Income
- -239.89M
- EBITDA
- -144.69M
- Earnings Per Share (EPS)
- -0.57
Cash Flow
In the last 12 months, operating cash flow was -64.25M and capital expenditures -200.16M, giving a free cash flow of -264.41M billion.
- Operating Cash Flow
- -64.25M
- Free Cash Flow
- -264.41M
- Free Cash Flow per Share
- -0.63
Dividends & Yields
Adimmune Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.84%
- Earnings Yield
- -3.39%
Stock Price Statistics
- Beta
- 0.46
- 52-Week Price Change
- -10.16%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 26.56
- Average Volume (3m)
- 1.02M
Important Dates
Adimmune Corporation upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Adimmune Corporation as a current ratio of 2.12, with Debt / Equity ratio of 57.25%
- Current Ratio
- 2.12
- Quick Ratio
- 1.75
- Debt to Market Cap
- 0.35
- Net Debt to EBITDA
- -4.45
- Interest Coverage Ratio
- -11.54
Taxes
In the past 12 months, Adimmune Corporation has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Adimmune Corporation EV to EBITDA ratio is -198.89, with an EV/FCF ratio of -30.75.
- EV to Sales
- 5.93
- EV to EBITDA
- -198.89
- EV to Free Cash Flow
- -30.75
- EV to Operating Cash Flow
- -126.53
Balance Sheet
Adimmune Corporation has TWD 1.82B in cash and marketable securities with TWD 3.03B in debt, giving a net cash position of -TWD 1.20B billion.
- Cash & Marketable Securities
- TWD 1.82B
- Total Debt
- TWD 3.03B
- Net Cash
- -TWD 1.20B
- Net Cash Per Share
- -TWD 2.80
- Tangible Book Value Per Share
- TWD 11.11
Margins
Gross margin is 22.36%, with operating margin of -18.85%, and net profit margin of -17.05%.
- Gross Margin
- 22.36%
- Operating Margin
- -18.85%
- Pretax Margin
- -15.42%
- Net Profit Margin
- -17.05%
- EBITDA Margin
- -2.98%
- EBIT Margin
- -18.36%
Analyst Forecast
The average price target for Adimmune Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -15.13%
- EPS Growth Forecast
- 36.74%
